KR20230112609A - 상염색체 우성 저칼슘혈증 타입 1(adh1)의 치료를 위한 트리페닐 칼시라이틱 화합물 - Google Patents

상염색체 우성 저칼슘혈증 타입 1(adh1)의 치료를 위한 트리페닐 칼시라이틱 화합물 Download PDF

Info

Publication number
KR20230112609A
KR20230112609A KR1020237012476A KR20237012476A KR20230112609A KR 20230112609 A KR20230112609 A KR 20230112609A KR 1020237012476 A KR1020237012476 A KR 1020237012476A KR 20237012476 A KR20237012476 A KR 20237012476A KR 20230112609 A KR20230112609 A KR 20230112609A
Authority
KR
South Korea
Prior art keywords
cltx
dose
cca
blood
total daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237012476A
Other languages
English (en)
Korean (ko)
Inventor
시몬 브루스
조나단 폭스
라메이 사니-그로쏘
알리 코메일리
아난트 스리다르
매리 스콧 로버츠
마이클 티. 콜린스
레이첼 아이. 가프니
켈리 비. 엘. 로츠코
아이리스 알. 하틀리
카렌 에이. 포조
Original Assignee
캘시리틱스 테라퓨틱스, 인코포레이티드
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캘시리틱스 테라퓨틱스, 인코포레이티드, 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 캘시리틱스 테라퓨틱스, 인코포레이티드
Publication of KR20230112609A publication Critical patent/KR20230112609A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020237012476A 2020-09-18 2021-09-16 상염색체 우성 저칼슘혈증 타입 1(adh1)의 치료를 위한 트리페닐 칼시라이틱 화합물 Pending KR20230112609A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063080165P 2020-09-18 2020-09-18
US63/080,165 2020-09-18
US202163159397P 2021-03-10 2021-03-10
US63/159,397 2021-03-10
PCT/US2021/050677 WO2022060987A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Publications (1)

Publication Number Publication Date
KR20230112609A true KR20230112609A (ko) 2023-07-27

Family

ID=78087574

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012476A Pending KR20230112609A (ko) 2020-09-18 2021-09-16 상염색체 우성 저칼슘혈증 타입 1(adh1)의 치료를 위한 트리페닐 칼시라이틱 화합물

Country Status (10)

Country Link
US (1) US20220087961A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213829A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542932A (cg-RX-API-DMAC7.html)
KR (1) KR20230112609A (cg-RX-API-DMAC7.html)
AU (1) AU2021343475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192684A1 (cg-RX-API-DMAC7.html)
IL (1) IL301409A (cg-RX-API-DMAC7.html)
MX (1) MX2023003129A (cg-RX-API-DMAC7.html)
TW (1) TW202227046A (cg-RX-API-DMAC7.html)
WO (1) WO2022060987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
WO2024220796A1 (en) * 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
CN116648243A (zh) * 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂

Also Published As

Publication number Publication date
EP4213829A1 (en) 2023-07-26
WO2022060987A1 (en) 2022-03-24
IL301409A (en) 2023-05-01
MX2023003129A (es) 2023-08-04
US20220087961A1 (en) 2022-03-24
AU2021343475A1 (en) 2023-06-01
TW202227046A (zh) 2022-07-16
AU2021343475A9 (en) 2024-05-02
CA3192684A1 (en) 2022-03-24
JP2023542932A (ja) 2023-10-12

Similar Documents

Publication Publication Date Title
US20220152058A1 (en) Methods and compositions for treating various disorders
Linglart et al. Hypophosphatasia
US20220323445A1 (en) Reducing immunogenicity to pegloticase
US12465631B2 (en) Reducing immunogenicity to pegloticase
Palmer A physiologic-based approach to the evaluation of a patient with hyperkalemia
KR100445946B1 (ko) 폐고혈압 치료법
US6645959B1 (en) Method for treating postoperative ileus
US20220409620A1 (en) Reducing immunogenicity to pegloticase
US20220087961A1 (en) Treatment methods of triphenyl calcilytic compounds
BR112020000842A2 (pt) composições e métodos para tratamento do hiv
CN116916907A (zh) 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物
EP1253945B1 (en) Ace inhibitor-vasopressin antagonist combinations
CN121219002A (zh) Glp-1r拮抗作用改善胃肠外科手术后的营养
TW202506101A (zh) 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療
EP1280555B1 (en) Pharmaceutical composition comprising furosemide and conivaptan for the treatment of congestive heart failure
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
US20250152557A1 (en) Methods for treating subjects with abdominal obesity hypertriglyceridemia and/or impaired glucose
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
US20210085711A1 (en) Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
WO2025235883A1 (en) Acoramidis for use in the treatment of renal dysfunction
CN120981229A (zh) 用于治疗先天性肾上腺皮质增生症的组合物和方法
WO2026032924A1 (en) Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough
Capsules et al. PrTeva-Sunitinib
Capsules et al. PrTARO-SUNITINIB
Kuk Coping with ulcers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902